Acute pancreatitis: recognition and management in AU general practice

What acute pancreatitis is

Acute pancreatitis is sudden inflammation of the pancreas triggered when digestive enzymes are activated inside the gland rather than in the small intestine. The result ranges from localised oedema that resolves within a few days to necrotising disease with systemic inflammatory response, multi-organ failure, and death.

Therapeutic Guidelines estimates an Australian incidence of 30–50 per 100,000 per year, with numbers climbing as obesity prevalence and prescribing of GLP-1 receptor agonists both rise. About 80% of episodes are mild; around 20% are moderately severe or severe. Knowing which category a patient is likely in determines how urgently to transfer them and how closely to follow them afterwards.

A. Core clinical — the AU general-practice framework

Diagnosing acute pancreatitis

The Revised Atlanta Classification (Banks, Gut 2013) requires at least two of three criteria for diagnosis:

1. Characteristic pain — epigastric, often with radiation to the back, worsening when lying flat, eased by sitting forward, reaching full intensity within hours.
2. Serum lipase or amylase above three times the upper limit of normal — lipase is preferred because it stays elevated longer (8–14 days vs 3–5 days for amylase) and is more specific.
3. Typical imaging findings on contrast CT, MRI, or abdominal ultrasound.

When two of three are present, imaging is not required to confirm the diagnosis; it is performed later to assess severity or identify a cause (ultrasound for gallstones), or in atypical presentations.

Severity classification

Severity	Definition	Approximate mortality
Mild	No organ failure, no local or systemic complications	Under 1%
Moderately severe	Transient organ failure lasting under 48 hours, or local complications (fluid collections, necrosis, pseudocyst)	Around 5%
Severe	Persistent organ failure lasting more than 48 hours ± local complications	15–25%

Organ failure is scored by the modified Marshall system across three systems — respiratory, cardiovascular, renal. A score of two or above in any system constitutes failure.

Causes in Australia

The common aetiological picture in Australian general practice:

• Gallstones 40–50% — small stones under 5 mm and microlithiasis carry the highest risk. Consider same-admission ultrasound.
• Alcohol 25–30% — usually after chronic heavy use; history best captured using the AUDIT tool.
• Drugs ~5% — the TGA issued a pancreatitis class advisory for GLP-1 receptor agonists covering semaglutide, liraglutide, dulaglutide, and tirzepatide. Other culprits include azathioprine, valproate, mesalazine, thiazides, and oestrogen.
• Hypertriglyceridaemia above 11 mmol/L — often familial chylomicronaemia worsened by alcohol or uncontrolled diabetes.
• Post-ERCP — in about 3–10% of procedures.
• Autoimmune (IgG4-related) — check IgG4 in recurrent idiopathic cases.
• Idiopathic 10–15% — many reveal microlithiasis or a genetic cause on detailed workup.
• Malignancy — pancreatic adenocarcinoma can obstruct the pancreatic duct and present as AP; flag in people over 50 with no obvious cause.

Red flags for severe disease

Any of the following at first contact suggest impending or established severe pancreatitis:

• Systolic BP under 100 mmHg, heart rate above 120, respiratory rate above 22, SpO₂ under 92%
• Anuria or urine output below 0.5 mL/kg per hour
• Corrected calcium below 2.0 mmol/L
• Lactate above 2 mmol/L
• Cullen’s sign (periumbilical bruising) or Grey-Turner’s sign (flank bruising) — late, specific signs of retroperitoneal haemorrhage
• New confusion

GP stabilisation before transfer

The GP role is to recognise, stabilise, and transfer — not to investigate fully. The sequence in the first 60 minutes:

1. Call 000 for category-1 ambulance (or RFDS for remote presentations). Pre-notify the receiving ED.
2. Intravenous access — 18-gauge cannula if possible.
3. Hartmann’s solution or lactated Ringer’s — 1 litre over one hour while awaiting transport. Avoid aggressive volumes (see evidence section).
4. Antiemetic — ondansetron 4–8 mg IV (caution with prolonged QT).
5. Analgesia — paracetamol 1 g IV or orally; opioid IV (fentanyl 25–50 µg or morphine 2.5–5 mg) once a transport plan is in place.
6. Nil by mouth strictly; nasogastric tube if there is persistent vomiting.
7. Oxygen to maintain SpO₂ 94–98%.
8. Document time of recognition, vital signs trend, drugs given, and destination. Hand over with ISBAR.
9. Do not delay transfer to perform imaging; do not give antibiotics without a specific indication.

B. Key evidence shifts in acute pancreatitis management

Several major trials over the past decade have reversed older teaching. Understanding them helps GPs give accurate information to patients and families about what to expect during admission.

Moderate, not aggressive, fluids

The WATERFALL trial (Buxbaum, NEJM 2022) compared aggressive fluid resuscitation (20 mL/kg bolus then 3 mL/kg/h) against moderate resuscitation (1.5 mL/kg/h) with Lactated Ringer’s. The aggressive arm was stopped early because of excess fluid overload without mortality benefit. Current guidelines recommend moderate balanced crystalloid titrated to perfusion targets — urine output at least 0.5 mL/kg/h and mean arterial pressure at least 65 mmHg.

Early enteral nutrition, not prolonged fasting

The PYTHON trial (Bakker, NEJM 2014) showed that nasogastric feeding performed as well as nasojejunal feeding; and both were better than total parenteral nutrition. The gut barrier is preserved by early enteral feeding, which reduces infectious complications. Current practice is to offer oral intake when tolerated — usually within 24–72 hours — with nasogastric tube feeding if the patient cannot eat. Total parenteral nutrition is reserved for failure of enteral routes.

Same-admission cholecystectomy for mild gallstone pancreatitis

The PONCHO trial (da Costa, Lancet 2015) showed that same-admission laparoscopic cholecystectomy reduced recurrent biliary events by around 75% compared with interval (6-week) cholecystectomy, with no increase in surgical complications. This is now standard care for mild gallstone acute pancreatitis.

No prophylactic antibiotics

The IAP/APA 2013 guidelines and ACG 2024 agree that prophylactic antibiotics in severe or necrotising pancreatitis do not reduce mortality but do increase resistant organisms and fungal infection. Antibiotics are used only for proven infected necrosis or identified extra-pancreatic infection.

Endoscopic step-up for walled-off necrosis

The TENSION trial (van Brunschot, Lancet 2018) established endoscopic transluminal drainage as equivalent to open surgical necrosectomy for infected walled-off necrosis, with fewer major complications. The step-up approach — percutaneous drainage first, then endoscopic transluminal drainage via lumen-apposing metal stent, then surgery only if those fail — is now the preferred pathway.

C. Conditions that can mimic acute pancreatitis

Condition	Discriminating feature
Perforated peptic ulcer	Rigid abdomen, free gas on erect chest X-ray; lipase usually normal or mildly elevated
Inferior myocardial infarction	ECG changes, troponin rise, diaphoresis — always perform an ECG in epigastric pain
Mesenteric ischaemia	Pain out of proportion to signs, severe acidosis, atrial fibrillation or vascular history
Cholangitis or cholecystitis	Right upper quadrant tenderness, Murphy’s sign, fever plus jaundice; can coexist with gallstone pancreatitis
Aortic dissection or leak	Hypotension, back pain, pulsatile mass; bedside ultrasound
Diabetic ketoacidosis	Known diabetes, ketonaemia; lipase can be mildly elevated in DKA without pancreatitis — interpret carefully
Ectopic pregnancy	Reproductive-age female; check serum beta-hCG

D. Australian operations

MBS items relevant to general practice

For the initial consultation, standard Level B (item 23), Level C (item 36), or Level D (item 44) applies depending on consultation length. Post-discharge survivorship care — alcohol, diabetes risk, mental health — can be structured under the GPCCMP (items 965 and 967). Mental Health Care Plans items 2715 and 2717 are appropriate for post-ICU anxiety, depression, or PTSD.

Investigation MBS items: abdominal ultrasound 55036; CT abdomen with contrast 56507; MRCP 63491; ECG 11700.

PBS medicines relevant to survivorship care

Pancreatic enzyme replacement therapy (Creon) is PBS Authority Required under Streamlined for documented exocrine insufficiency. Fenofibrate is on the general PBS schedule for hypertriglyceridaemia. Statins are on general schedule; despite a rare pancreatitis signal, net cardiovascular benefit is favourable and statins are not routinely withheld. Alcohol-cessation pharmacotherapy (naltrexone, acamprosate) is on general schedule via AMH.

Referral pathways

• Acute admission: emergency department — category 1; rural and remote: RFDS retrieval.
• Hepatobiliary surgeon: same-admission or interval cholecystectomy; walled-off necrosis.
• Gastroenterologist: ERCP when cholangitis or persistent biliary obstruction is confirmed; recurrent or idiopathic workup; autoimmune pancreatitis (IgG4).
• Endocrinologist: post-pancreatitis diabetes (type 3c is distinct from type 2 — often brittle and insulin-deficient); severe hypertriglyceridaemia.
• Dietitian: recovery nutrition, enzyme replacement titration, alcohol-related nutritional deficits.
• Alcohol and other drug services: for alcohol-related pancreatitis; see RACGP alcohol-use guidance.

GLP-1 receptor agonist note

The TGA has issued a class pancreatitis advisory for GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, tirzepatide). The absolute risk is small — approximately 1–2 excess events per 1,000 patient-years — but the class cardiovascular and renal benefits are substantial in the right patients. After an episode of pancreatitis attributed to a GLP-1 agent, cease the drug and document it in the allergy section. Whether to restart the class after recovery is a shared decision made with the patient and relevant specialist, weighing the cardiovascular and renal benefits against the pancreatitis signal.

E. Special populations

Older adults. Age above 60 is a component of the BISAP severity score. Frailty lowers the safe ceiling for aggressive fluid resuscitation. Post-pancreatitis diabetes is particularly problematic in older people who may already have type 2 diabetes or impaired renal function limiting diabetes pharmacotherapy options.

Pregnancy. Gallstones are more common during pregnancy. Acute pancreatitis in pregnancy carries higher risk of foetal loss, particularly in severe disease. Management principles are the same — fluid resuscitation, analgesia, early transfer — with obstetric input and caution around imaging modalities and medications that are contraindicated in pregnancy.

Rural and remote Australia. RFDS retrieval is the primary pathway for rural patients who cannot be transferred by road. Early recognition and stabilisation — IV access, fluid, analgesia, nil by mouth — buys time for retrieval. Remote Aboriginal and Torres Strait Islander communities have higher baseline rates of chronic disease and alcohol use, which influence both aetiology and severity.

Aboriginal and Torres Strait Islander Australians. Coordinate care via Aboriginal Medical Services or ACCHOs. The Aboriginal Health Worker MBS item 10987 supports chronic condition coordination under GPCCMP. Closing the Gap PBS co-payment applies for Creon, statins, and other ongoing treatments.

When to escalate

Transfer by category-1 ambulance is the default for all confirmed or suspected acute pancreatitis. Within the hospital setting, escalation to ICU is indicated for:

• Persistent single or multi-organ failure beyond 48 hours
• Haemodynamic instability not responding to fluid resuscitation
• Respiratory failure requiring ventilatory support
• Severe hypocalcaemia, coagulopathy, or refractory hyperglycaemia
• Infected necrosis requiring surgical or endoscopic intervention
• Suspected acute liver failure in severe disease

For post-discharge patients, return to the emergency department is indicated for: recurrent severe epigastric pain, fever, vomiting, jaundice, new confusion, or inability to take adequate fluid and nutrition by mouth.

What this article is and is not

This is general health information drawing on Therapeutic Guidelines, RACGP resources, the TGA pancreatitis safety advisory, and major randomised trials. It does not constitute personal medical advice and does not create a doctor–patient relationship. Treatment decisions for acute pancreatitis — including fluid volumes, analgesia, surgical timing, and post-pancreatitis care — are made by the treating team based on the individual’s full clinical picture.

For Australian consumer-friendly information: HealthDirect — Pancreatitis, Better Health Channel.

For medical emergencies: call 000.

---

Sources cited

1. Therapeutic Guidelines — Acute pancreatitis
2. RACGP — Pancreatitis in general practice (AFP)
3. TGA — GLP-1 receptor agonist pancreatitis class safety advisory
4. Banks PA et al. Revised Atlanta Classification 2012 — Gut 2013
5. Buxbaum JL et al. WATERFALL trial — NEJM 2022
6. Bakker OJ et al. PYTHON trial — NEJM 2014
7. da Costa DW et al. PONCHO trial — Lancet 2015
8. van Brunschot S et al. TENSION trial — Lancet 2018
9. IAP/APA Evidence-based Guidelines on Acute Pancreatitis — Pancreatology 2013
10. ACG Clinical Guideline: Management of Acute Pancreatitis 2024
11. Australian Medicines Handbook
12. HealthDirect — Pancreatitis
13. Better Health Channel — Pancreatitis